True Leaf: Upcoming Regulation A+ Crowdfunding Opportunity in Cannabis Industry

Ryan Allway

August 10th, 2017

News, Top News

The cannabis industry is expected to see rapid growth over the coming years. Canada remains the industry leader with its progressive laws governing cannabis, and the market continues to grow in the United States and Europe. There are many different ways for investors to capitalize on these trends, but the best investment opportunities combine short-term revenue and long-term potential.

In this article, we will look at True Leaf Medicine International Ltd. (CSE: MJ) (OTCQB: TRLFF) (FSE: TLA) and its plans to capitalize on the multi-billion dollar cannabis industry through its two wholly-owned subsidiaries, True Leaf Pet and True Leaf Medicine.

Click here to learn about the company’s upcoming Regulation A+ financing opportunity, and to receive an alert when it goes live.

Existing Revenue from True Leaf Pet

True Leaf’s subsidiary, True Leaf Pet, is focused on the pet industry where its non-psychoactive hemp-based pet products are already legal throughout the U.S., Canada, and Europe.

According to the American Pet Products Association, Americans will spend nearly $70 billion on their pets this year. This spending includes about $30 billion on food, $15 billion on over-the-counter medicine, and $16 billion on veterinary care products and services.

The company’s True Hemp™  supplement line comes in multiple formats including chews, oil and sticks. It offers all three formats in 3 specific functions:

  • True Hemp™ HIP+JOINT Support – Developed with hemp, green lipped mussel, and turmeric root to support joint health.
  • True Hemp™ CALMING Support – Contain hemp, L-theanine, and calming herbs to help provide calming support to pets.
  • True Hemp™ IMMUNE+HEART Support – Contain hemp, DHA, and other antioxidants to support heart and immune health.

Management has developed manufacturing partnerships and distribution centers in the U.S., Canada, and Europe while continuing to bolster its product line through a combination of internal development and potential acquisitions. The goal is to become a market leader in the hemp + cannabis pet supplement industry as consumers become increasingly aware of the wonder-plant’s potential to support several medical conditions for pets.

Click here to learn about the company’s upcoming Regulation A+ financing opportunity, and to receive an alert when it goes live.

True Leaf Medicine: Long-term Potential as a Licensed Producer

True Leaf Medicine applied to become a licensed producer of dried cannabis flower under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) in July of 2013. Since then, the company has developed a plan to build a 48,000 square foot facility, that is in the final stage of Health Canada’s licensing process. Management anticipates generating upwards of $45 million in annual revenue, when in full operations, starting next summer if it secures approval.

According to Deloitte, the Canadian cannabis industry could reach C$22.6 billion in size following the legalization of recreational cannabis. The analyst expects the retail market to capture anywhere between C$4.9 billion and C$8.7 billion each year, while the ancillary market for growers, testing labs, lighting, security, and other products could push the market to C$12.7 billion to C$22.6 billion. And, this doesn’t include taxes, licensing, and tourism revenues.

Licensed producers have already generated tremendous interest among investors with several companies trading at lofty valuations, including:

  • Canopy Growth Corp. (TSX: WEED) – C$1.42 Billion
  • Aurora Cannabis Inc. (TSX: ACB) – C$949.81 Million
  • Aphria Inc. (TSX: APH) – C$885.67 Million

True Leaf plans to develop products to support medical conditions like nausea, insomnia, chronic pain, and epilepsy after securing its production and sales licenses. The company also has longer-term expansion plans for its production facility as Canada’s adult-use regulations kick in and the country becomes a leading exporter of cannabis products worldwide. Investors should factor in these expansion opportunities when valuing the stock.

Looking Ahead

True Leaf Medicine International Ltd. (CSE: MJ) (OTCQB: TRLFF) (FSE: TLA) has tremendous potential within the burgeoning cannabis industry. As True Leaf Pet revenues grow, the company’s stock could see potential upside given that competitors are valued at 2x to 5x revenue. True Leaf Medicine could see even more upside over the coming years since licensed producers have achieved valuations of between $60 million and over $1.5 billion in Canada.

For more information regarding the company’s new crowdfunding campaign, click here.

SEC Disclaimer: An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that True Leaf Medicine Inc. may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement here. You should read the offering circular before making any investment.

No money or consideration is being solicited by the information on this webpage or any other communication and, if sent, money will not be accepted and will be promptly returned.  No offer by a potential investor to buy our securities can be accepted and, if made, any such offer can be withdrawn before qualification of this offering by the SEC.  A potential investor’s indication of interest does not create a commitment to purchase the securities we are offering. Any such indication of interest may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance is given and all other requirements to accept an investment from a potential investor are met after the offering qualification date.

Forward-Looking Statements: This presentation contains forward-looking statements and management may make additional forward-looking statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results, and therefore we refer you to a more detailed discussion of the risks and uncertainties in the Company’s filings with the Securities & Exchange Commission when available. The forward-looking statements contained in this presentation are made only as of today, and True Leaf Medicine Inc. is under no obligation to revise or update these forward-looking statements.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements drafted by our in house team or provided by an affiliate., a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. received fees for producing and presenting high quality and sophisticated content on along with financial and corporate news.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit:

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer